ART Advanced Research Technologies Molecular Imaging Platform Showcased at the World Molecular Imaging Congress in France
10 September 2008 - 1:40AM
Marketwired
ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a
Canadian medical device company and a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries,
announced today that current research relating to its molecular
imaging products will be presented at the World Molecular Imaging
Congress (WMIC), being held at the Nice Acropolis Convention Centre
in Nice, France, from September 10 to 13, 2008. ART is also
featuring the Optix� and Fenestra� preclinical product offering as
an exhibitor at the event (booth #211), in the Exhibit Hall of the
Nice Acropolis Convention Center.
Prior to the start of the meeting - on Wednesday, September 10 -
ART will hold a ART User Forum, where Optix users and research
scientists will present their work, and provide an opportunity for
potential clients to learn about new developments and applications
available for the Optix system, as well as the capability for
translational research using the SoftScan� breast imaging device.
Both products are based on the proprietary time domain technology
developed by ART.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan� optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. Finally, the Fenestra�
line of molecular imaging contrast products provides image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART
is commercializing some of these products in a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at
www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in ART's most recent Annual Information
Form and the financial statements for the year ended December 31,
2007, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca ART Advanced
Research Technologies Inc. Dino DiCamillo, Vice President, Global
Sales and Marketing, Preclinical Research 514-832-0777
ddicamil@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024